Return to Trial Database

BTCRC-HEM17-092

Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092

Status

Study Completed

Cancer Type(s)

Study Contact

Trial Locations

All sites in which the trial BTCRC-HEM17-092 being conducted in.

No data was found